Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Christian HengstenbergJaya ChandrasekharSamantha SartoriThierry LefevreGhada MikhailNicolas MeneveauChristophe TronRaban JegerChristian KupattBirgit VogelSerdar FarhanSabato SorrentinoMadhav SharmaClayton SnyderOliver HusserPeter BoekstegersRainer HambrechtJulian WidderDavid Hildick-SmithMarco De CarloPeter WijngaardEfthymios DeliargyrisDebra BernsteinUsman BaberRoxana MehranProdromos AnthopoulosGeorge D Dangasnull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
Prior or new-onset AF is noted in more than one-third of patients undergoing transfemoral TAVR. Despite greater baseline comorbidities than non-AF patients, AF was not associated with significantly higher risk of adjusted 30-day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group.
Keyphrases
- transcatheter aortic valve replacement
- atrial fibrillation
- aortic stenosis
- aortic valve
- ejection fraction
- patients undergoing
- left atrial
- oral anticoagulants
- catheter ablation
- left atrial appendage
- end stage renal disease
- transcatheter aortic valve implantation
- aortic valve replacement
- direct oral anticoagulants
- heart failure
- newly diagnosed
- percutaneous coronary intervention
- peritoneal dialysis
- venous thromboembolism
- clinical trial
- prognostic factors
- weight loss
- mitral valve
- patient reported outcomes
- phase iii
- glycemic control
- adipose tissue